PRCG CEO Jim Haggerty in Adweek on Johnson & Johnson’s Response to Cancer Claims
PRCG CEO Jim Haggerty addresses weaknesses in Johnson & Johnson’s response to the $72 million order linking the plaintiff’s death from ovarian cancer with her usage of products containing talcum. He contrasts this response with Lumber Liquidators’ more consumer-focused approach.
“They clearly were unprepared for what to do if there was a big verdict. The blog post feels like it’s written by a combination of scientists and lawyers.”
–Jim Haggerty in Adweek